- Conditions
- Dementia-related Psychosis
- Interventions
- Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 27
- States / cities
- Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
- Interventions
- [18F]-PI2620 PET scan
- Diagnostic Test
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- ACP-204
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 19
- States / cities
- Costa Mesa, California • Fresno, California • Hialeah, Florida + 6 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ML-007C-MA, Placebo
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 20 more
- Conditions
- Alzheimer's Disease
- Interventions
- Olanzapine, Quetiapine, Risperidone, Citalopram
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 34
- States / cities
- Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more
- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- ACP-204, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 1,074 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 45
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 29 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ML-007C-MA
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 55 Years to 91 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Doral, Florida • Miami, Florida
- Conditions
- Dementia
- Interventions
- Citalopram, Risperidone
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania